Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
[PDF][PDF] Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - blood, 2019 - researchgate.net
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - Blood, 2019 - europepmc.org
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
[HTML][HTML] Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - Blood, 2019 - Elsevier
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
T Winkler, X Fan, J Cooper, R Desmond… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - Blood, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Eltrombopag (EPAG) received approval from
the US Food and Drug Administration for the treatment of refractory severe aplastic anemia …
the US Food and Drug Administration for the treatment of refractory severe aplastic anemia …
[HTML][HTML] Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - Blood, 2019 - ncbi.nlm.nih.gov
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.
T Winkler, X Fan, J Cooper, R Desmond, DJ Young… - Blood, 2019 - europepmc.org
Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …